AAP News Vol. 14 No. 10 October 1998, p. 10
© 1998 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

FDA licenses first vaccine for use in rotavirus infection prevention

The U.S. Food and Drug Administration on Aug. 31 granted licensure for Rotashield® Rotavirus vaccine, a live, tetravalent vaccine for use in the prevention of rotavirus gastroenteritis. The rotavirus vaccine is approved for oral administration to infants in a three-dose series at 2, 4, and 6 months of age.

The approval of the rotavirus vaccine was based on evaluation of efficacy data from three large scale, placebo-controlled clinical efficacy trials conducted in the United States and Europe. The rotavirus vaccine will be distributed by Wyeth Lederle Vaccines, a unit of Wyeth - Ayerst Laboratories, and was available for marketing in Sept. 1998.